What Is GIP? Glucose-Dependent Insulinotropic Polypeptide Explained

Peptide biology explained

GIP — glucose-dependent insulinotropic polypeptide — is a 42-amino-acid gut hormone and one of the two main “incretins,” alongside GLP-1. Released by intestinal K-cells after you eat, its headline job is to tell the pancreas to release insulin, but only when blood sugar is already elevated. GIP also acts on fat tissue, bone, brain and the glucagon-producing cells of the pancreas, and it sits at the center of a genuinely unresolved question in obesity science — because both activating and blocking its receptor have improved metabolic outcomes.

What GIP is

GIP’s modern name is glucose-dependent insulinotropic polypeptide; its original name was gastric inhibitory polypeptide (same abbreviation). It circulates as an active 42-amino-acid peptide cut from a larger 153-amino-acid precursor, and it is secreted by K-cells in the proximal small intestine (the duodenum and jejunum) in response to nutrients — especially fat and glucose. Its receptor, GIPR, is a class B G-protein-coupled receptor found on many cell types.

Together with GLP-1 (which comes from intestinal L-cells), GIP is one of the two dominant incretin hormones — gut signals that link eating to insulin release.

The incretin effect

Here is the observation that started it all: give someone glucose by mouth, and they release far more insulin than if you give the same amount of glucose intravenously to reach an identical blood-sugar level. That extra insulin, triggered by hormones released from the gut, is called the incretin effect.

In healthy people, the incretin effect accounts for a large share — commonly cited as up to about 70% — of the insulin released after oral glucose, and GIP and GLP-1 together are responsible for most of it. The word “glucose-dependent” is the key to GIP’s safety story: it drives insulin release only when glucose is elevated, so on its own it carries a low intrinsic risk of causing low blood sugar.

What GIP does in the body

GIP’s best-known action is on the pancreatic beta cells, where it stimulates glucose-dependent insulin secretion. But its receptor shows up in several other tissues:

In adipose (fat) tissue, GIP promotes nutrient uptake and fat storage. On the pancreatic alpha cells it can raise glucagon, especially when glucose is on the lower side — a counter-regulatory action. It also has documented roles in bone metabolism and in the brain, where GIP signaling is linked to appetite and energy balance. This spread of actions is part of why GIP biology is more complicated than “a hormone that raises insulin.”

GIP in type 2 diabetes

The incretin effect is blunted in type 2 diabetes. A notable detail is that GIP secretion is largely preserved in type 2 diabetes, but its insulinotropic action is markedly impaired — GIP is still there, but the beta cells respond poorly to it. This “preserved but ineffective” GIP response is considered a major reason the incretin effect is reduced in the disease.

Both incretins are also short-lived. The enzyme DPP-4 (dipeptidyl peptidase-4) clips two amino acids off the N-terminus and inactivates them within minutes — intact GIP survives only a few minutes in circulation. That rapid breakdown is exactly why drug developers engineer long-acting, DPP-4-resistant versions.

The GIP puzzle: block it or boost it?

Here is where GIP gets genuinely interesting — and unsettled. Both activating the GIP receptor and blocking it (each combined with GLP-1 action) have produced weight loss in studies.

On the agonism side, tirzepatide (a dual GIP/GLP-1 agonist) delivers strong glucose and weight results. On the antagonism side, a GIP-receptor-blocking molecule combined with a GLP-1 agonist has advanced into late-stage trials, also producing weight loss. One leading — but unproven — hypothesis is that sustained receptor activation eventually desensitizes the receptor, so long-term agonism may functionally resemble antagonism. The honest summary is that scientists do not yet fully agree on how engaging the GIP receptor helps, and the question is an active area of research.

GIP in modern drugs

GIP is no longer a footnote to GLP-1. Tirzepatide put GIP-receptor agonism on the map as part of a dual agonist, and retatrutide adds GIP into a triple GIP/GLP-1/glucagon agonist. Understanding GIP is now essential to understanding the whole newer generation of metabolic peptides.

Frequently asked questions

What does GIP stand for?

Glucose-dependent insulinotropic polypeptide. Its older name was gastric inhibitory polypeptide, which shares the same abbreviation.

Where is GIP made?

By K-cells in the proximal small intestine (the duodenum and jejunum), released after eating, especially in response to fat and glucose.

How is GIP different from GLP-1?

Both are incretin hormones that boost glucose-dependent insulin. GIP comes from K-cells and also acts on fat and bone; GLP-1 comes from L-cells and additionally slows gastric emptying and reduces appetite more strongly.

Why do both GIP agonists and antagonists cause weight loss?

That is an unresolved scientific question. One hypothesis is that constant agonism desensitizes the receptor, blurring the line between activating and blocking it. Research is ongoing.

Informational only — not medical advice · 21+. This article explains the biology of GIP and does not provide treatment or dosing guidance.